‹ ›
MYP_049755
← PREVIOUS NEXT → BACK
Basic Information
Unnamed
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
38 amino acids
C204H314N54O71S2
Standard
Sequence
MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL
Physicochemical Analysis
4723.12 Da
4.14
-7.39
-7.67
-0.1945
-1.10
0.58
-0.15
59.97
82.11
0.0789
12490.00
12490.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
2090.00
-19.34
69.0
67.0
164.0
331.0
6.0
45.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0222075 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
HIV 098-T20 | CEM4 cells
0.008257 μM
IC50
Mammalian: 30 h; Yeast: >20 h; E. coli: >10 h
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. | Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. | Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. | DOI:10.1073/pnas.0701478104 | PMID:17640899 PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0236335 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
HIV 098 | CEM4 cells
0.006775 μM
IC50
Mammalian: 30 h; Yeast: >20 h; E. coli: >10 h
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. | Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. | Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. | DOI:10.1073/pnas.0701478104 | PMID:17640899 PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0287859 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
HIV 098-T651 | CEM4 cells
1.053 μM
IC50
Mammalian: 30 h; Yeast: >20 h; E. coli: >10 h
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. | Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. | Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. | DOI:10.1073/pnas.0701478104 | PMID:17640899 PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0354019 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 098
PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0392300 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
CEM4
0.032 μg/mL
IC50
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 3 of 4